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Abstract
Background: HbA1c test is widely used for glycemic monitoring of diabetic patients. This study aimed to evaluate
clinical performance of different assays for classification of patients into controlled and uncontrolled group base on
ADA recommendations.
Method: A total of 154 samples from patients with diabetes type 2 with HbA1c concentration covering the whole
clinical range were analyzed by four commercially methods; D-10 Hb A1c (Bio-Rad Laboratories), Cobas Integra 400
(Roche Diagnostics), NycoCard Reader II (Axis-Shield) and DS5 (Drew Scientific). For each individual assay, patient’s
results were classified into controlled and uncontrolled groups (less or more than three decision levels; 6.5 %, 7 %
and 8 %) compared to D10 results as reference method. The frequency of each group and also sensitivity,
specificity, negative and positive predictive value were estimated.
Results: We found a significant correlation between assays (r: 0.937–0.945). Sensitivity, specificity, and positive and
negative predictive values of the evaluated method to identify uncontrolled patients were as follows: 49.2–95.7 %,
86.5–100 %, 89.1–100 %, and 52.9–93.3 %; respectively.
Conclusions: Results show that some HbA1c assays capability to classify diabetic patients according to HbA1c level
is still unacceptable.
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Introduction
Measurement of HbA1c concentration can be consid-
ered as a useful indicator of glycemic control in diabetic
patients. Moreover, it is documented that high HbA1c
levels are correlated with development of different dia-
betes complications. Measurement of HbA1c has more
advantages over both assessment of the fasting plasma
glucose and glucose tolerance test. It is more convenient,
does not require fasting, has increased preanalytical sta-
bility, is less likely to differ in different days due to stress
or illness [1, 2].
HbA1c testing is also useful in diseases other than dia-
betes. Van’t Riet in a 10 year follow-up study (Hoorn
Study) found that, in non-diabetic persons between 50
and 75 years of age, HbA1c measurement was a superior
predictor of 10 year cardiovascular events (fatal and
non-fatal) and all-cause mortality, in comparison with
fasting and 2 h postprandial glucose [3]. Moreover, the
findings of the North American Atherosclerosis Risk in
Communities (ARIC) study demonstrated that HbA1c
was a better predictor of diabetes and cardiovascular dis-
ease in comparison with fasting glucose in patients
without diagnosed diabetes [4]. Reducing Hb A1c con-
centrations to 7 % or below is demonstrated to be corre-
lated with significant decrease in the rate of different
microvascular complications of diabetes. Although it is
recommended that Hb A1c levels in non-pregnant
adults should be kept less than 7 %, more stringent A1c
(6.5 %) and mild A1c goals (8 %) may also be recom-
mended for some patient considering their specific
situation [2].
Results of one single assessment of HbA1c can provide
clinicians with the best determinant of glycemic control
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in patients and clinical decision-making can be effect-
ively guided by it [5]. Therefore, it can be concluded that
the assays for determination of HbA1c levels need to be
accurate, precise and consistent to be able to effectively
employed by clinicians.
Currently, there exist an exceeding number of 30 differ-
ent HbA1c assays on the market and they all perform
based on two different principles, one of them being the
separation of Hb fractions, and the other, on chemical
reaction. It is noteworthy however that all of the men-
tioned assays need to be standardized based on National
Glycohemoglobin Standardization Program (NGSP) [6–8].
When choosing an HbA1c measurement method, la-
boratories should first analyze the method in terms of its
being NGSP certified (potential for optimal performance)
and then assess proficiency testing data (both current and
past surveys) to predict the actual performance of it. Al-
though selection of a NGSP certified method which has
successfully passed proficiency testing is very important, it
does not still does not guarantee optimal performance in
all laboratories [9].
Despite considerable achievements of NGSP in terms
of validity of different HbA1c techniques, it is docu-
mented that the existing variability among NGSP-
certified methods can still undermine clinical diagnostic
value of HbA1c testing [10, 11].
The current study is designed to assess discrepancies
between HbA1c results obtained by D10-HPLC as refer-
ence method and other evaluated assays to determine
the diversity in categorization of individual patients in
regard to their glycemic control (HbA1c less or more
than three decision level; 6.5 %, 7 % and 8 %). We
assessed the variability of the results obtained from dif-
ferent techniques in two groups: those with controlled
blood glucose levels, and the patients with uncontrolled
glucose concentrations.
Materials and methods
A total of 154 samples from diabetic patients with
HbA1c concentration covering the whole clinical range,
were obtained through venipuncture into sterile tubes
containing the EDTA K2 and tested with 4 assays within
2 days. No more inclusion criteria were used.
It needs to be mentioned that the study was approved
by the Ethics Committee of Endocrinology metabolism
Research Institute and all participants gave written in-
formed consent.
HbA1c measurement was performed concurrently in
all cases by four commercially available assays:
1. D-10 Hb A1c (Bio-Rad Laboratories, Hercules, CA),
Ion exchange HPLC method
2. Cobas Integra 400 (Roche Diagnostics, Mannheim,
Germany), Immunoassay
3. NycoCard Reader II, (Axis-Shield, Oslo, Norway),
Boronate affinity chromatography
4. DS5, (Drew Scientific, Le Rheu, France), Ion
exchange chromatography
Of these, three methods are currently certified by the
National Glycohemoglobin Standardization Program
(D-10 Hb A1c, Cobas Integra 400 and NycoCard
Reader II).
According to recommendations from the American
Diabetes Association (ADA), three decision level for dia-
betic patients monitoring (6.5 %, 7 % and 8 %) were con-
sidered and patients were classified based on their
glycemic status by each method (HbA1c < cut off and
HbA1c ≥ cut off ). After calculation of frequency of each
group for each method, sensitivity, specificity, and posi-
tive and negative predictive values of the different
method were estimated. D10 was considered as the ref-
erence method. Total precision of each assay was also
evaluated using CLSI EP15-A2 protocol [12].
Data were processed with the statistical software,
SPSS version 15. Mean and Standard Deviation, p value
and correlation coefficient were calculated. Sensitivity,
specificity, and positive predictive values (PPV) and
negative predictive values (NPV) of the three assays
were estimated.
Results
Total precision (in term of CV%) were less than 1.6 %,
1.0 %, 3.1 % and 3.3 % for D10, cobas integra 400,
Nycocard reader II and DS5 respectively. The mean
± SD value of HbA1c was significantly higher when
measured by D10 (7.59 % ± 1.43 %) than when estimated
with the Nycocard reader II (6.87 % ± 1.17 %, r: 0.937,
P < 0.05) and DS5 (6.69 ± 1.47 %, r: 0945, P < 0.05) and
almost same compared to cobas integra 400 (7.66 ±
1.45, r: 0.944, P: 0.06). For each individual assay,
patient’s results were classified into controlled and
uncontrolled groups compared to D10 results and the
frequencies of each group were estimated (Tables 1, 2, 3).
In three cut points when using Nycocard, 17.1 %, 26.5 %
and 50.8 % of patients could be misclassified as controlled.
The same results (27.4 %, 33.3 % and 46 %) were found
when using DS5. The results were less than 9.5 % for
cobas integra. Sensitivity, Specificity, Negative and positive
predictive value were shown in Table 4.
Discussion
The finding of our study demonstrated that although
different measurement methods for HbA1c concentra-
tions show very good correlation but might be different
in patients with different glycemic control goals. This
variation in patients, in turn, might cause confusion in
clinicians and affect the proper decision-making.
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In our study, Nycocard reader II and DS5 were less
sensitive than cobas integra at three cut points: 6.5 %,
7 %, and 8 %. When Nycocard or DS5 were used,
17.1 %–50.8 % and 27.4–46 % of patients were
mistakenly identified as the control group. Cobas
integra 400 had best ability to detect patients who their
results were more or less than predefined decision level
and only 4.3 %, 6.9 % and 9.5 % could be underesti-
mated. Fortunately positive predictive value for all
evaluated assay was more than 89 % which means the
results more than decision level are much more reliable.
In similar study designed by García-Alcalá et al., the
authors evaluated the performance of an immunotur-
bidimetric inhibition assay (Dimension, Dade Behring)
and compared it with the HPLC method (Biorad D10).
Their findings demonstrated sensitivity and specificity
of 78 % and 88 %, respectively, in screening patients
with HbA1c levels more than 7 % [5]. In the present
study, we observed that immunoassay method (cobas
integra) demonstrated sensitivity and specificity of
93.1 % and 86.5 % respectively at HbA1c level 7 %. In
a study designed by Schwartz et al., point-of-care test-
ing devices (POCT) were investigated and the results
were compared with that of the central labs with
which all of them were aligned to DCCT (Diabetes
Control and Complications Trial) and NGSP. Their
findings demonstrated that the sensitivity of POCT
devices in detecting patients with HbA1c levels higher
than 7 % was 81.8 % [13]. In the current study, the
sensitivity of Nycocard reader II as a POCT device
was estimated about 73.5 %. Few studies have been
done about HbA1c assays performance in Iran with
the main focus on persistence of bias in different
assay. Karami study showed unacceptable bias in four
HbA1c assays including Nycocard [14]. The same
results have been achieved by Keramati et al. study
Table 1 Classification of patients at HbA1c level 6.5 %
D10
Cobas Integra 400 <6.5 ≥6.5 Total
<6.5 34 5 39
≥6.5 3 112 115
Total 37 114 154
Nycocard reader II <6.5 ≥6.5 Total
<6.5 37 20 58
≥6.5 0 97 97
Total 37 117 154
DS5 <6.5 ≥6.5 Total
<6.5 36 32 68
≥6.5 1 85 86
Total 37 117 154
Table 2 Classification of patients at HbA1c level 7 %
D10
Cobas Integra 400 <7 ≥7 Total
<7 45 7 52
≥7 7 95 102
Total 52 102 154
Nycocard reader II <7 ≥7 Total
<7 52 27 81
≥7 0 75 75
Total 52 102 154
DS5 <7 ≥7 Total
<7 52 34 86
≥7 0 68 68
Total 52 102 154
Table 3 Classification of patients at HbA1c level 8 %
D10
Cobas Integra 400 <8 ≥8 Total
<8 84 6 90
≥8 7 57 64
Total 91 63 154
Nycocard reader II <8 ≥8 Total
<8 90 32 122
≥8 1 31 32
Total 91 63 154
DS5 <8 ≥8 Total
<8 90 29 119
≥8 1 34 35
Total 91 63 154
Table 4 Sensitivity and Specificity of three assays at different
Cut Point Compared to D10 Result
Sensitivity % Specificity % PPV % NPV %
A1C level 6.5 %
Cobas Integra 400 95.7 91.9 97.4 87.2
Nycocard reader II 82.9 100.0 100.0 64.9
DS5 72.6 97.3 98.8 52.9
A1C level 7 %
Cobas Integra 400 93.1 86.5 93.1 86.5
Nycocard reader II 73.5 100.0 100.0 65.8
DS5 66.7 100.0 100.0 60.5
A1C level 8 %
Cobas Integra 400 90.5 92.3 89.1 93.3
Nycocard reader II 49.2 98.9 96.9 73.8
DS5 54.0 98.9 97.1 75.6
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which evaluated five HbA1c assays including Nycocard
and DS5 [15].
Our results show that being NGSP certified is not
enough and the more attention to proficiency testing
results and also validation of assays in each laboratory is
recommended.
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